Tarsus Pharmaceuticals, Inc. (TARS) SEC Filings & Earnings Calls

Integration risk and dilution from stock issuance; milestone payments contingent on regulatory and commercial success.

“milestone payments up to an aggregate amount equal to $350,000,000 ... tiered revenue sharing payments in the low-to-mid single digits”

Dilution risk: issuance of 2.1M shares and pre-funded warrants increases share count by ~5% based on current outstanding.

“2,098,519 shares of common stock... and pre-funded warrants to purchase up to 133,625 shares.”

Lock-up expiration risk: after 90 days, insiders may sell shares, potentially pressuring stock price.

“Each of the Company’s directors and officers entered into a lock-up agreement... for a period of 90 days.” · word for word

Single product dependency

“We are heavily dependent on the continued successful commercialization of XDEMVY and the successful development, regulatory approvals, and commercialization of our current and future product candidates.” · word for word

Customer concentration

“For the three and six months ended June 30, 2026, the Company had one and two customers, respectively, each of whom exceeded 10% of total gross product sales. These customers on a combined basis accounted for 66.4% and 76.8% of total gross product sales for the respective periods.” · word for word

Supply chain concentration

“This reliance on third parties and single source suppliers increases the risk that we will not have sufficient quantities of XDEMVY, our product candidates, or compounds or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our commercialization or development efforts, as we expect XDEMVY and each of our ” · word for word

Dependence on single product XDEMVY for all revenue; pipeline still in clinical stages.

“All product sales from XDEMVY; pipeline programs are Phase 2/3 with topline data expected in 2027-2028.”

Integration risk from pending Alkeus acquisition and recent iRenix acquisition.

“Pending acquisition of Alkeus Pharmaceuticals... completed the acquisition of iRenix Medical.” · word for word

Increasing SG&A spend may pressure profitability if revenue growth slows.

“SG&A expenses: were $150.7 million compared to $103.0 million for the same period in 2025.” · word for word

Integration risk: acquiring Alkeus adds complexity; milestone payments up to $350M could strain resources if not achieved.

“Milestone payments up to an aggregate amount equal to $350,000,000... and tiered revenue sharing payments.” · word for word

Dilution risk: issuance of $180M in stock upfront plus potential contingent stock consideration increases share count.

“$180,000,000 of shares of common stock... and Contingent Stock Consideration.” · word for word

Regulatory risk: HSR waiting period and other closing conditions may delay or prevent closing.

“The closing of the Acquisition is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.” · word for word

Loss of commercial leadership could impact sales execution

“Departure of Chief Commercial Officer without immediate replacement announced.”

Dilution from stock consideration and future milestone payments may impact shareholders.

“Issued 607,093 shares as part of upfront consideration; up to $490M in future milestone payments.”

Single product dependency

“We are heavily dependent on the continued successful commercialization of XDEMVY and the successful development, regulatory approvals, and commercialization of our current and future product candidates.” · word for word

Customer concentration

“For the three months ended March 31, 2026 and 2025, the Company's two largest customers each exceeded 10% of total gross product sales. These customers on a combined basis accounted for 79.0% and 72.3% of total gross product sales for the respective periods.” · word for word

Single product dependency

“XDEMVY is the only approved product; pipeline candidates (TP-04, TP-05) are still in development.”

Pipeline execution risk

“Pipeline goals for 2025 were not fully met; some milestones achieved 0%.”

Default on Santa Monica Place and Twenty Ninth Street mortgages

“At December 31, 2025, the Company was in compliance with all applicable loan covenants under its agreements, with the exception of Santa Monica Place, as discussed above. The $76.5 million mortgage loan (at the Company's pro rata share) on Twenty Ninth Street is in default as of February 6, 2026.”

Elevated interest expense from refinancing below-market rate loans

“While interest rates have begun to decrease, they remain elevated and the Company expects to incur increased interest expense from the refinancing or extension of loans that may carry below-market interest rates.”

Dependence on successful execution of Path Forward Plan

“Essential goals of the Path Forward Plan include: Deleverage the capital structure, with a focus on reducing the Company's Net Debt to Adjusted EBITDA leverage ratio over the next two to three years; Invest in and fortify the Company's key assets in the portfolio; Proactively consolidate selected joint venture assets over time that are core to the Company's ”

Concentration of stock ownership

“The concentration of our stock ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval.” · word for word

High SG&A spend relative to revenue; commercial costs may pressure profitability.

“SG&A expenses $130.7M vs $69.0M in Q4 2024, driven by commercial and marketing costs.”

Dependence on single product XDEMVY for revenue.

“All product sales from XDEMVY; pipeline still early-stage.”

Forward-looking statements subject to risks; no audited financials.

“This presentation contains forward-looking statements that involve risks and uncertainties.” · word for word

High SG&A spend ($108.6M in Q3) relative to revenue, driven by commercial launch costs including DTC advertising.

“Selling, general and administrative (SG&A) expenses: were $108.6 million compared to $57.9 million for the same period in 2024.” · word for word

Single product dependency

“We are heavily dependent on the successful commercialization of XDEMVY and the development, regulatory approval, and commercialization of our current and future product candidates.” · word for word

Customer concentration

“For the three months ended September 30, 2025, the Company's two largest customers each individually accounted for more than 10% of total gross product sales, which on a combined basis accounted for 77.1% of total gross product sales.”

Supply chain concentration

“This reliance on third parties and single source suppliers increases the risk that we will not have sufficient quantities of XDEMVY, our product candidates, or compounds or that such supply will not be available to us at an acceptable cost.” · word for word

Continued losses expected

“We have continued to incur significant losses and negative cash flows from operations since our inception and anticipate that we will continue to incur significant expenses and potential losses for the foreseeable future.” · word for word